Loading...
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti, G V Vynnychenko, I Park, K Ichinose, Y Kubota, K Pirker, R Galiulin, R Ciuleanu, T Sydorenko, O
Scagliotti, G V
Vynnychenko, I
Park, K
Ichinose, Y
Kubota, K
Pirker, R
Galiulin, R
Ciuleanu, T
Sydorenko, O
Citations
Altmetric:
Abstract
We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsquamous non-small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma.
Description
Date
2012-08-10
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 233.65 KB
Keywords
Type
Article
Citation
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. 2012, 30 (23):2829-36 J Clin Oncol